Fludrocortisone

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

Fludrocortisone (brand name: Florinef) is a synthetic corticosteroid hormone used in treatment of postural hypotension and adrenal insufficiency, including Addison's disease. It is frequently used off-label as a treatment for postural orthostatic tachycardia syndrome (POTS) and orthostatic intolerance (OI). In adrenal insufficiency, it is generally taken together with hydrocortisone.

Fludrocortisone is mostly a mineralocorticoid, but it has very weak glucocorticoid effects.[1]It mimics the function of aldosterone, increasing blood sodium levels and therefore, blood volume.[2]

Use in chronic fatigue syndrome[edit | edit source]

*In 1998, a study by Phillip K. Peterson, et al, showed that low-dose fludrocortisone does not provide sufficient benefit to patients with chronic fatigue syndrome. Using the 36-Item Short-Form Health Survey, a reaction time test, and a treadmill exercise test, they found no observed improvement in the severity of any symptom. Likewise, blood pressure and heart rate readings were unaffected by treatment.[3]

ME/CFS patients often have OI or POTS and these conditions could improve by taking fludrocortisone.[4][5]

Side effects and drug interactions[edit | edit source]

It is important to discuss fludrocortisone's side effects[6] and possible drug interactions[7] with your doctor and pharmacist.

Notable studies[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. Chrousos, George; Pavlaki, Aikaterini N.; Magiakou, Maria Alexandra (2000). De Groot, Leslie J.; Chrousos, George; Dungan, Kathleen; Feingold, Kenneth R.; Grossman, Ashley; Hershman, Jerome M.; Koch, Christian; Korbonits, Márta; McLachlan, Robert, eds. "Glucocorticoid Therapy and Adrenal Suppression". Endotext. South Dartmouth (MA): MDText.com, Inc. PMID 25905379 – via NCBI NLM NIH Bookshelf. 
  2. LLC, Revolvy,. ""Fludrocortisone" on Revolvy.com". www.revolvy.com. Retrieved Aug 14, 2018. 
  3. 3.03.1 Peterson, Phillip K.; Pheley, Alfred; Schroeppel, Jill; Schenck, Carlos; Marshall, Paul; Kind, Allan; Haugland, J. Mark; Lambrecht, Lawrence J.; Swan, Suzanne (Apr 27, 1998). "A Preliminary Placebo-Controlled Crossover Trial of Fludrocortisone for Chronic Fatigue Syndrome". Archives of Internal Medicine. 158 (8): 908. doi:10.1001/archinte.158.8.908. ISSN 0003-9926. 
  4. "Proposed Diagnostic Criteria for ME/CFS". nationalacademiesofmedicine.org. 2015. 
  5. Wright Clayton, Ellen; Algeria, Margarita; Bateman, Lucinda; Chu, Lily; Cleeland, Charles; Davis, Ronald; Diamond, Betty; Ganiats, Theodore; Keller, Betsy (Mar 16, 2015). Nancy Klimas; A Martin Lerner; Cynthia Murlow; Benjamin Natelson; Peter Rowe; Michale Shelanski. "Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". National Academy of Medicine Education: 107–119. doi:10.17226/19012 – via NAP.EDU. 
  6. "Fludrocortisone Side Effects in Detail - Drugs.com". Drugs.com. Retrieved Aug 14, 2018. 
  7. "Fludrocortisone Drug Interactions - Drugs.com". Drugs.com. Retrieved Aug 14, 2018. 

Postural orthostatic tachycardia syndrome (POTS) - A form of orthostatic intolerance where the cardinal symptom is excessive tachycardia due to changing position (e.g. from lying down to sitting up).

Adverse reaction - Any unintended or unwanted response to the treatment under investigation in a clinical trial.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.